FSD Pharma Chairman & CEO to Present at 22nd Annual BIO CEO & Investor Conference in NYC

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"\n\n\n\nFSD Pharma Chairman & CEO to Present at 22nd Annual BIO CEO & Investor Conference in NYC\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nFSD Pharma Chairman & CEO to Present at 22nd Annual BIO CEO & Investor Conference in NYC\nCanada NewsWire\nTORONTO, Feb. 5, 2020\n\n\n\nTORONTO, Feb. 5, 2020 /CNW/ - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (\"FSD Pharma\" or the \"Company\") announces that Raza Bokhari, MD, Executive Co-Chairman and Chief Executive Officer, accompanied by FSD Pharma Biosciences leadership, will be participating in the 22nd Annual BIO CEO & Investor conference, including presenting a company overview at 9:45 a.m. ET on Monday, February 10, 2020.\n\n \n \n\n \nAbout BIO CEO & Investor Conference\nThe BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. The event features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities.\nAbout FSD Pharma\nFSD Pharma is a specialty biotech pharmaceutical R&D company focused on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system.\nThrough its acquisition of Prismic Pharmaceuticals in Q2 2019, FSD Pharma is also making an effort to help address the opioid crisis by developing opioid-sparing prescription drugs utilizing the micronized formulations of palmitolylethanolamide (PEA). The Company intends to initiate Phase 1 first-in-human safety and tolerability trials for its lead candidate, PP 101 micro-PEA during 1Q20.\nFSD's wholly-owned subsidiary, FV Pharma, is a licensed producer under Canada's Cannabis Act and Regulations, having received its cultivation license on October 1...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B